EVOTEC SE - SPON ADR (EVO) Stock Price, Quote, News and Overview
NASDAQ:EVO - Nasdaq - US30050E1055 - ADR - Currency: USD
EVO Quote, Performance and Key Statistics
3.6
+0.33 (+10.09%)
The current stock price of EVO is 3.6 USD. In the past month the price increased by 2.27%. In the past year, price decreased by -49.08%.
EVO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 19.56 | 161.38B | ||
| DHR | DANAHER CORP | 24.94 | 133.67B | ||
| A | AGILENT TECHNOLOGIES INC | 19.3 | 29.22B | ||
| IQV | IQVIA HOLDINGS INC | 12.92 | 25.37B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 24.42 | 20.94B | ||
| WAT | WATERS CORP | 27.04 | 19.10B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 29.91 | 14.60B | ||
| ICLR | ICON PLC | 9.95 | 11.50B | ||
| ILMN | ILLUMINA INC | 29.06 | 11.27B | ||
| RVTY | REVVITY INC | 18.74 | 11.03B | ||
| AVTR | AVANTOR INC | 15.1 | 10.29B | ||
| MEDP | MEDPACE HOLDINGS INC | 23.46 | 8.96B |
Related stock screener links
About EVO
Company Profile
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The company is headquartered in Hamburg, Hamburg and currently employs 5,007 full-time employees. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Company Info
EVOTEC SE - SPON ADR
Essener Bogen 7
Hamburg HAMBURG DE
CEO: Werner Lanthaler
Employees: 5022
Company Website: https://www.evotec.com/
Investor Relations: http://www.evotec.com/en/investor-relations/stock-information
Phone: 4940560810
EVOTEC SE - SPON ADR / EVO FAQ
What is the stock price of EVOTEC SE - SPON ADR today?
The current stock price of EVO is 3.6 USD. The price increased by 10.09% in the last trading session.
What is the ticker symbol for EVOTEC SE - SPON ADR stock?
The exchange symbol of EVOTEC SE - SPON ADR is EVO and it is listed on the Nasdaq exchange.
On which exchange is EVO stock listed?
EVO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for EVOTEC SE - SPON ADR stock?
13 analysts have analysed EVO and the average price target is 6.96 USD. This implies a price increase of 93.43% is expected in the next year compared to the current price of 3.6. Check the EVOTEC SE - SPON ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EVOTEC SE - SPON ADR worth?
EVOTEC SE - SPON ADR (EVO) has a market capitalization of 1.28B USD. This makes EVO a Small Cap stock.
How many employees does EVOTEC SE - SPON ADR have?
EVOTEC SE - SPON ADR (EVO) currently has 5022 employees.
What are the support and resistance levels for EVOTEC SE - SPON ADR (EVO) stock?
EVOTEC SE - SPON ADR (EVO) has a support level at 3.3 and a resistance level at 3.94. Check the full technical report for a detailed analysis of EVO support and resistance levels.
Is EVOTEC SE - SPON ADR (EVO) expected to grow?
The Revenue of EVOTEC SE - SPON ADR (EVO) is expected to grow by 10.32% in the next year. Check the estimates tab for more information on the EVO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy EVOTEC SE - SPON ADR (EVO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EVO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EVO, evaluating the profitability, health, valuation and growth aspects
- EVOTEC SE - SPON ADR (EVO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EVOTEC SE - SPON ADR (EVO) Sales and EPS estimates to see what analysts future expectations are.
- EVOTEC SE - SPON ADR (EVO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EVOTEC SE - SPON ADR (EVO) Insider and Institutional Ownership to learn about the owners and their transactions.
- EVOTEC SE - SPON ADR (EVO) Stock Chart to make your own analysis
- EVOTEC SE - SPON ADR (EVO) Latest news and press-releases to stay up to date.
Does EVOTEC SE - SPON ADR (EVO) stock pay dividends?
EVO does not pay a dividend.
When does EVOTEC SE - SPON ADR (EVO) report earnings?
EVOTEC SE - SPON ADR (EVO) will report earnings on 2025-08-13, before the market open.
What is the Price/Earnings (PE) ratio of EVOTEC SE - SPON ADR (EVO)?
EVOTEC SE - SPON ADR (EVO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.63).
What is the Short Interest ratio of EVOTEC SE - SPON ADR (EVO) stock?
The outstanding short interest for EVOTEC SE - SPON ADR (EVO) is 0.21% of its float. Check the ownership tab for more information on the EVO short interest.
EVO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to EVO. When comparing the yearly performance of all stocks, EVO is a bad performer in the overall market: 82.67% of all stocks are doing better.
EVO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EVO. EVO may be in some trouble as it scores bad on both profitability and health.
EVO Financial Highlights
Over the last trailing twelve months EVO reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS decreased by -136.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.61% | ||
| ROE | -17.69% | ||
| Debt/Equity | 0.43 |
EVO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 75% to EVO. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 74% and a revenue growth 10.32% for EVO